Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMHN Avmapki Fakzynja Coverage & Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.731

    Clinical Policy: Avutometinib; Defactinib (Avmapki Fakzynja Co-Pack)

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.731 alerts

    Get alerted when Policy CP.PHAR.731 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, initial and continued authorization requirements, dosing limits, contraindications, therapeutic alternatives, and prior authorization expectations for Avmapki Fakzynja Co-Pack across Commercial, HIM, and Medicaid lines of business.

    Policy Summary
    Payermhn
    PolicyClinical Policy: Avutometinib; Defactinib (Avmapki Fakzynja Co-Pack)
    Policy CodePolicy CP.PHAR.731
    Change TypeInitial policy creation
    Effective DateSep 1, 2025
    Last ReviewAug 1, 2025
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results or other clinical information) supporting that member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Policy created May 15, 2025 with P&T approval date 08.25.25.

    1

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered Indication (FDA-approved)
    6/12Approval durations (initial/continued months)
    3Required prior systemic therapy

    Coverage Summary & Indications

    Avmapki Fakzynja Co-Pack received accelerated approval for the treatment of adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. Coverage stance: covered_with_criteria. Scope: applies to Commercial, HIM, and Medicaid lines of business.

    Key Thresholds
    Age≥ 18 years
    Avmapki weekly dose (first 3 weeks of each 4-week cycle)≤ 6.4 mg (8 capsules) per week
    Fakzynja daily dose (first 3 weeks of each 4-week cycle)≤ 400 mg (2 tablets) per day
    Minimum therapy duration prior to continued coverage≥ 30 days

    Initial Therapy Criteria

    I. Initial Approval Criteria - Ovarian Cancer

    Covered when ALL of the following are met:

    • Diagnosis of LGSOC
    • Prescribed by or in consultation with an oncologist
    • Age ≥ 18 years≥ 18 years
    • Disease is recurrent
    • Disease is positive for KRAS mutation
    • Avmapki Fakzynja Co-Pack is not prescribed concurrently with any other agents for LGSOC
    • Member has received prior systemic therapy (see Appendix B)

    I. Initial Approval Criteria - Other diagnoses/indications

    If not listed above, meet ONE of the following:

    • 1: If drug label recently changed within last 6 months and change not reflected in policy, follow applicable formulary/no-coverage or non-formulary policy

      References: CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16

    • 2: If requested use is not listed under coverage-not-authorized section and above does not apply, refer to off-label use policy for relevant line of business

      References: CP.CPA.09, HIM.PA.154, CP.PMN.53

    Continuation Therapy Criteria

    II. Continued Therapy - Ovarian Cancer

    Continued coverage when ALL of the following are met:

    • Currently receiving medication via Centene benefit, or documentation supports current receipt for a covered indication and ≥ 30 days of therapy≥ 30 days
    • Member is responding positively to therapy
    • Avmapki Fakzynja Co-Pack is not prescribed concurrently with any other agents for LGSOC
    • Member must use avutometinib and defactinib, if available, unless contraindicated or clinically significant adverse effects are experienced
    • Dose increase requirement (a or b)

    Diagnoses / Indications Not Authorized

    III. Diagnoses/Indications Not Authorized

    Not covered unless exception applies:

    • Non-FDA approved indications that are not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety per off-label use policies

      References: CP.CPA.09, HIM.PA.154, CP.PMN.53

    Applicable Codes

    Product availabilitymixed
    avumetinib 0.8 mg capsuleco-packaged capsule
    defactinib 200 mg tabletco-packaged tablet

    Provider Actions & Prior Authorization Requirements

    Documentation Required

    Submission of supporting documentation

    Provider must submit office chart notes, laboratory results, or other clinical information supporting that the member meets all approval criteria.

    Prior Authorization

    Prescriber specialty requirement

    The prescription must be by an oncologist or written in consultation with an oncologist.

    Prior Authorization

    Dose justification for off-guideline dosing

    If the requested dose exceeds the specified limits, the prescriber must submit supporting evidence from practice guidelines or peer‑reviewed literature to justify the off‑guideline dosing.

    Clinical Evidence & Approval Basis

    Approval basis: Accelerated approval based on tumor response rate and duration of response; continued approval may require verification of clinical benefit in a confirmatory trial. Primary references: Avmapki Fakzynja Co-Pack Prescribing Information (Verastem, May 2025) and the NCCN Drugs and Biologics Compendium and ovarian cancer guideline.

    Background

    Avmapki Fakzynja Co-Pack is a co‑packaged product containing avutometinib and defactinib; both agents are kinase inhibitors. The product is supplied as avumetinib 0.8 mg capsules and defactinib 200 mg tablets in a co‑packaged presentation.

    The co‑pack is approved under an accelerated approval pathway for the indication: treatment of adult patients with KRAS‑mutated recurrent low‑grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. Dosing recommended for LGSOC during the first 3 weeks of each 4‑week cycle is Avmapki 3.2 mg PO twice weekly (Day 1 and Day 4) and Fakzynja 200 mg PO BID, until disease progression or unacceptable toxicity.

    Definitions and Policy Metadata
    LGSOC (term)low-grade serous ovarian cancer
    FDA (term)Food and Drug Administration
    Policy numberCP.PHAR.731
    Effective date09.01.25
    Last review date

    Revision History

    2025-05-15CreatedLatest

    Policy created May 15, 2025 with P&T approval date 08.25.25. Initial policy creation and approval; no prior version indicated.

    Policy Summary
    Payermhn
    PolicyClinical Policy: Avutometinib; Defactinib (Avmapki Fakzynja Co-Pack)
    Policy CodePolicy CP.PHAR.731
    Change TypeInitial policy creation
    Effective DateSep 1, 2025
    Last ReviewAug 1, 2025
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results or other clinical information) supporting that member meets all approval criteria.
    SourceLink
    On This Page
    Coverage Summary & IndicationsInitial Therapy CriteriaContinuation Therapy CriteriaDiagnoses / Indications Not AuthorizedApplicable CodesProvider Actions & Prior Authorization RequirementsClinical Evidence & Approval BasisBackgroundRevision History
  1. Member must use avutometinib and defactinib, if available, unless contraindicated or clinically significant adverse effects are experienced
  2. Dose requirement (a or b)

    • a. Dose does not exceed for the first 3 weeks of every 4-week cycle

      • i: Avmapki: 6.4 mg (8 capsules) per week≤ 6.4 mg per week
      • ii: Fakzynja: 400 mg (2 tablets) per day≤ 400 mg per day
    • b: Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence)
  3. Prescribed regimen must be FDA-approved or recommended by NCCN
    • a. New dose does not exceed for the first 3 weeks of every 4-week cycle

      • i: Avmapki: 6.4 mg (8 capsules) per week≤ 6.4 mg per week
      • ii: Fakzynja: 400 mg (2 tablets) per day≤ 400 mg per day
    • b: New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence)
  4. Prescribed regimen must be FDA-approved or recommended by NCCN
  5. II. Continued Therapy - Other diagnoses/indications

    If not listed above, meet ONE of the following:

    • 1: If drug label recently changed within last 6 months and change not reflected in policy, follow applicable formulary/no-coverage or non-formulary policy

      References: CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16

    • 2: If requested use is not listed under coverage-not-authorized section and above does not apply, refer to off-label use policy for relevant line of business

      References: CP.CPA.09, HIM.PA.154, CP.PMN.53

    Billing Rule

    Use of both agents when available

    Requests must use both avutometinib and defactinib if both agents are available, unless there is a contraindication or the member experiences clinically significant adverse effects.

    08.25
    Payer metadata (line of business)Commercial, HIM, Medicaid